Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes

被引:100
作者
Ogilvie, P
Paoletti, S
Clark-Lewis, I
Uguccioni, M
机构
[1] Inst Biomed Res, CH-6500 Bellinzona, Switzerland
[2] Univ British Columbia, Biochem Res Ctr, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.1182/blood-2002-09-2773
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Eotaxin-3 (CCL26) belongs to the group of CC chemokines that attract eosinophils, basophils, and Th2 lymphocytes. Like eotaxin (CCL11) and eotaxin-2 (CCL24), eotaxin-3 mediates its activity through CCR3. Here we show that eotaxin-3 also binds to CCR2 on monocytes and CCR2-transfected cells. In contrast to monocyte chemotactic protein 1 (MCP-1; CCL2), eotaxin-3 does not trigger intracellular calcium mobilization, enzyme release, or phosphorylation of the mitogen-activated protein (MAP) kinase ERK and induces a weak chemotaxis in monocytes. instead, eotaxin-3 inhibits MCP-1-mediated responses, thus acting as a natural antagonist for CCR2. This study also demonstrates that eotaxin-3 promotes active movement of monocytes away from a gradient of eotaxin-3 in vitro. This repellent effect is amplified when an additional gradient of MCP-1 is applied, demonstrating that the 2 mechanisms are synergistic. Eotaxin-3 effects on monocytes; are largely abolished when cells are pretreated with MCP-1 or CCR2 antagonists Like MCP-1-mediated migration, repulsion is sensitive to Bordetella pertussis toxin, indicating the involvement of G(i) protein-coupled receptors. However, using transfected cells expressing CCR2 we could not detect F-actin formation or an active movement away induced by eotaxin-3, suggesting that either expression of a single receptor type is not sufficient to mediate cell repulsion or that the used transfected cell lines lack additional interaction molecules that are required for reverse migration. Eotaxin-3 was expressed by vascular endothelial cells and was essential for endothelial transmigration of eosinophils. Our data provide a mechanism by which 2 chemokine gradients that are oriented in opposite directions could cooperate in efficiently driving out monocytes from blood vessels into tissue.
引用
收藏
页码:789 / 794
页数:6
相关论文
共 48 条
[1]   Regulatory effects of eotaxin, eotaxin-2, and eotaxin-3 on eosinophil degranulation and superoxide anion generation [J].
Badewa, AP ;
Hudson, CE ;
Heiman, AS .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2002, 227 (08) :645-651
[2]   Eotasin: A VIC (very important chemokine) of allergic inflammation? [J].
Baggiolini, M .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (03) :587-587
[3]   Eotaxins - Contributing to the diversity of eosinophil recruitment and activation [J].
Bandeira-Melo, C ;
Herbst, A ;
Weller, PF .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2001, 24 (06) :653-657
[4]   Regulation of human eotaxin-3/CCL26 expression: Modulation by cytokines and glucocorticoids [J].
Banwell, ME ;
Tolley, NS ;
Williams, TJ ;
Mitchell, TJ .
CYTOKINE, 2002, 17 (06) :317-323
[5]   Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge [J].
Berkman, N ;
Ohnona, S ;
Chung, FK ;
Breuer, R .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2001, 24 (06) :682-687
[6]  
Blanpain C, 1999, BLOOD, V94, P1899
[7]   Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis [J].
Boring, L ;
Gosling, J ;
Cleary, M ;
Charo, IF .
NATURE, 1998, 394 (6696) :894-897
[8]   Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice [J].
Boring, L ;
Gosling, J ;
Chensue, SW ;
Kunkel, SL ;
Farese, RV ;
Broxmeyer, HE ;
Charo, IF .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (10) :2552-2561
[9]   CHEMICAL SYNTHESIS, PURIFICATION, AND CHARACTERIZATION OF 2 INFLAMMATORY PROTEINS, NEUTROPHIL ACTIVATING PEPTIDE-1 (INTERLEUKIN-8) AND NEUTROPHIL ACTIVATING PEPTIDE-2 [J].
CLARKLEWIS, I ;
MOSER, B ;
WALZ, A ;
BAGGIOLINI, M ;
SCOTT, GJ ;
AEBERSOLD, R .
BIOCHEMISTRY, 1991, 30 (12) :3128-3135
[10]  
COLOTTA F, 1984, J IMMUNOL, V132, P936